Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Shares Are Soaring Today While Moderna and Novavax Shares Are Sinking

By Keith Speights - Updated Mar 3, 2020 at 2:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Inovio's accelerated timeline for its coronavirus vaccine program is shaking things up for three biotech stocks.

What happened

You might call it a case of coronavirus stock mayhem. Shares of Inovio Pharmaceuticals (INO 5.78%) were soaring 14.8% as of 10:38 a.m. EST on Tuesday. At the same time, shares of two other biotechs that are developing experimental coronavirus vaccines, Moderna (MRNA 4.87%) and Novavax (NVAX 10.83%), were sinking by 7.5% and 12.3%, respectively.

These moves were caused by the same news. Inovio announced before the market opened on Tuesday that it was accelerating the timeline for developing its DNA vaccine INO-4800 for COVID-19, the disease caused by the novel coronavirus.

Inovio plans to begin human clinical trials in the U.S. in April, with clinical trials following shortly thereafter in China and South Korea. The results are expected to be published in the fall of 2020. Inovio plans to produce 1 million doses of its experimental COVID-19 vaccine by the end of the year.

Coronavirus vaccine bottles

Image source: Getty Images.

So what

It's pretty clear why Inovio stock jumped on the news of its accelerated COVID-19 vaccine schedule. It also makes sense why shares of Moderna and Novavax would drop.

The first company to develop a safe and effective vaccine for COVID-19 will likely rake in sales as countries across the world stock up on it. Companies that are later in developing COVID-19 vaccines could find themselves largely left behind.

Moderna announced on Feb. 24 that its coronavirus vaccine mRNA-1273 was ready for human clinical trials. The biotech stated then that vials of the vaccine had already been shipped to the National Institute of Allergy and Infectious Diseases (NIAID) for use in a U.S. phase 1 clinical study. Two days later, Novavax announced that it plans to begin a phase 1 clinical study evaluating a nanoparticle-based COVID-19 vaccine in the spring of 2020. 

All three of these small biotechs appear to be in a close race. Inovio's projection that it will produce 1 million doses of INO-4800 by the end of 2020, though, seems to have given the company at least a slight lead in the eyes of investors.

Now what

There's one thing that investors can almost certainly count on: All three of these biotech stocks will remain highly volatile. Positive news from one company will boost its shares and cause the other two stocks to decline. But the situation could change quickly with good news from another biotech. Keep in mind that other big drugmakers are also working on experimental COVID-19 vaccines. 

Instead of focusing only on the coronavirus prospects for these biotechs, a better approach is to look at the companies' overall prospects. For example, Inovio's lead pipeline candidate is VGX-3100, a drug targeting cervical dysplasia. Moderna is evaluating its experimental cytomegalovirus (CMV) vaccine mRNA-1647 in a mid-stage clinical study. Novavax expects to soon report results from a late-stage study of its flu vaccine NanoFlu.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.00 (10.83%) $5.57
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.83 (5.78%) $0.10
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$149.81 (4.87%) $6.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.